Therapy of deep fungal infection in haematological malignancy

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 6, 1997, Pages 779-788

  Barnes, Rosemary A ^a   Rogers, T R F ^b   Cohen, J ^b   Denning, D W ^c   Evans, E G V ^d   Hay, R J ^e   Prentice, A G ^f   Speller, D C E ^g   Warnock, D W ^h   Warren, R E ⁱ  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e GUY S HOSPITAL   (United Kingdom)

^f DERRIFORD HOSPITAL   (United Kingdom)

^g CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

^h Public Health Laboratory   (United Kingdom)

ⁱ ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; GROWTH FACTOR; INTRALIPID; ITRACONAZOLE; LIPOSOME; PYRROLE DERIVATIVE; VORICONAZOLE;

ASPERGILLOSIS; BLOOD DISEASE; BONE MARROW TOXICITY; CANDIDIASIS; CARDIOTOXICITY; CHILL; DEEP FUNGAL INFECTION; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG MONITORING; DRUG RESISTANCE; DRUG TOLERABILITY; DRUG TOXICITY; DRUG WITHDRAWAL; FEVER; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LIVER TOXICITY; MUCORALES; MYCOSIS; ORAL DRUG ADMINISTRATION; PYREXIA IDIOPATHICA; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; FLUCYTOSINE; HEMATOLOGIC NEOPLASMS; HUMANS; MYCOSES;

EID: 2642601102     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.6.779     Document Type: Review

References (78)

1. Bodey, G., Bueltmann, B., Duguid, W., Gibbs, D., Hanak, H., Hotchi, M. et al. (1992). Fungal infections in cancer patients: an international autopsy survey. European Journal of Clinical Microbiology and Infectious Diseases 11, 99-109.
2. McWhinney, P. H. M., Kibbler, C. C., Hamon, M. D., Smith, O. P., Gandhi, L., Berger, L. A. et al. (1993). Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clinical Infectious Diseases 17, 397-404.
3. EORTC International Antimicrobial Therapy Cooperative Group. (1989). Empiric antifungal therapy in febrile granulocytopenic patients. American Journal of Medicine 86, 668-72.
4. Anttila, V. J., Ruutu, P., Bondestam, S., Jansson, S. E., Nordling, S., Farkkila, M. et al. (1994). Hepatosplenic yeast infection in patients with acute leukemia: a diagnostic problem. Clinical Infectious Diseases 18, 979-81.
5. Talbot, G. H., Huang, A. & Provencher, M. (1991). Invasive aspergillus rhinosinusitis in patients with acute leukemia. Reviews of Infectious Diseases 13, 219-32.
6. Young, R. C., Bennett, J. E., Vogel, C. L., Carbone, P. P. & DeVita, V. T. (1970). Aspergillosis: the spectrum of disease in 98 patients. Medicine 49, 147-73.
7. Duthie, R. & Denning, D. W. (1995). Aspergillus fungemia: report of two cases and review. Clinical Infectious Diseases 20, 598-605.
8. Edwards, J. E. (1991). Invasive candida infections. Evolution of a fungal pathogen. New England Journal of Medicine 324, 1060-2.
9. von Eiff, M., Roos, N., Fegeler, W., von Eiff, C., Zuhlsdorf, M., Glaser, J. et al. (1994). Pulmonary fungal infections in immunocompromised patients: incidence and risk factors. Mycoses 37, 329-35.
10. Barloon, T. J., Galvin, J. R., Mori, M., Stanford, W. & Gingrich, R. D. (1991). High-resolution ultrafast chest CT in the clinical management of febrile bone marrow transplant patients with normal or non-specific chest roentgenograms. Chest 99, 928-33.
11. Blum, U., Windfuhr, M., Buitrago-Tellez, C., Sigmund, G., Herbst, E. W. & Langer, M. (1994). Invasive pulmonary aspergillosis: MRI, CT, and plain radiographic findings and their contribution for early diagnosis. Chest 106, 1156-61.
12. Flynn, P. M., Shenep, J. L., Crawford, R. & Hughes, W. T. (1995). Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients. Clinical Infectious Diseases 20, 964-70.
13. Crawford, S. W., Hackman, R. C. & Clark, J. G. (1989). Biopsy diagnosis and clinical outcome of persistent pulmonary lesions after marrow transplantation. Transplantation 48, 266-71.
14. Denning, D. W. & Stevens, D. A. (1990). Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Reviews of Infectious Diseases 12, 1147-201.
15. Hawkins, C. & Armstrong, D. (1984). Fungal infections in the immunocompromised host. Clinical Haematology 13, 599-630.
16. Gallis, H. A., Drew, R. H. & Pickard, W. W. (1990). Amphotericin-B: 30 years of clinical experience. Reviews of Infectious Diseases 12, 308-29.
17. Viscoli, C., Castagnola, E., Van Lint, M. T., Moroni, C., Garaventa, A., Rossi, M. R. et al. (1996). Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. European Journal of Cancer 32A, 814-20.
18. Lecciones, J. A., Lee, J. W., Navarro, E. E., Witebsky, F. G., Marshall, D., Steinberg, S. M. et al. (1992). Vascular catheter-associated fungaemia in patients with cancer. Analysis of 155 episodes. Clinical Infectious Diseases 14, 875-83.
19. Pizzo, P. A., Robichaud, K. J., Gill, F. A. & Witebsky, F. G. (1982). Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. American Journal of Medicine 72, 101-11.
20. Burks, L. C., Aisner, J., Fortner, C. L. & Wiernik, P. H. (1980). Meperidine for the treatment of shaking chills and fevers. Archives of Internal Medicine 140, 483-4.
21. Gigliotti, F., Shenep, J. L., Lott, L. & Thornton, D. (1987). Induction of prostaglandin synthesis as the mechanism responsible for the chills and fevers produced by infusing amphotericin. Journal of Infectious Diseases 156, 784-9.
22. Shadomy, S., Brummer, D. L. & Ingroff, A. V. (1973). Light sensitivity of prepared solutions of amphotericin B. American Review of Respiratory Disease 107, 303-4.
23. Smith, S. R., Galloway, M. J., Reilly, J. T. & Davies, J. M. (1988). Amiloride prevents amphotericin B related hypokalaemia in neutropenic patients. Journal of Clinical Pathology 41, 494-7.
24. Khoo, S. H., Bond, J. & Denning, D. W. (1994). Administering amphotericin B - a practical approach. Journal of Antimicrobial Chemotherapy 33, 203-13.
25. Maksymiuk, A. W., Thongprasert, S., Hopfer, R., Luna, M., Fainstein, V. & Bodey, G. P. (1984). Systemic candidiasis in cancer patients. American Journal of Medicine 77, Suppl. 4D, 20-7.
26. Denning, D. W. (1996). Therapeutic outcome in invasive aspergillosis. Clinical Infectious Diseases 23, 608-15.
27. Kurup, V. P. & Kumar, A. (1991). Immunodiagnosis of aspergillosis. Clinical Microbiology Reviews 4, 439-56.
28. Karp, J. E., Burch, P. A. & Merz, W. G. (1988). An approach to intensive antileukaemia therapy in patients with previous invasive aspergillosis. American Journal of Medicine 85, 203-6.
29. Powderly, W. G., Kobayashi, G. S., Herzig, G. P. & Medoff, G. (1988). Amphotericin B resistant yeast infection in severely immunocompromised patients. American Journal of Medicine 84, 826-32.
30. Ringden, O., Meunier, F., Tollemar, J., Ricci, P., Tura, S., Kuse, E. et al. (1991). Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy 28, Suppl. B, 73-82.
31. Zoubek, A., Emminger, W., Emminger-Schmidmeier, W., Peters, C., Pracher, E., Grois, N. et al. (1992). Conventional vs. liposomal amphotericin B in immunocompromised children. Pediatric Hematology and Oncology 9, 187-90.
32. Mills, W., Chopra, R., Linch, D. C. & Goldstone, A. H. (1994). Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. British Journal of Haematology 86, 754-60.
33. Ribaud, P. & Gluckman, E. (1996). Critical review of lipid amphotericin B formulations as treatment of invasive aspergillosis in patients with hematological disorders or bone marrow transplantation. Journal de Mycologie Medicale 6, Suppl. 1, 17-20.
34. Adler-Moore, J. P. & Proffitt, R. T. (1993). Development, characterization, efficacy and mode of action of Ambisome, a unilamellar liposomal formulation of amphotericin B. Journal of Liposome Research 3, 429-50.
35. Ellis, M., Spence, D., Meunier, F., De Pauw, B., Bogaerts, M., Van der Cam, B. et al. (1996). Randomised multicentre trial of 1 mg/kg versus 4 mg/kg liposomal amphotericin B (Ambisome) in the treatment of invasive aspergillosis. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. Abstract LM 39, p. 287. American Society for Microbiology, Washington, DC.
36. Prentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D. et al. (1997). A randomised comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin (PUO) in neutropenic patients. British Journal of Haematology 98, 711-8.
37. Kruger, W., Sobottka, I., Stockschlader, M., Mross, K., Hoffknecht, M., Russmann, B. et al. (1996). Fatal outcome of disseminated candidosis after allogeneic bone marrow transplantation under treatment with liposomal and conventional amphotericin B. A report of 4 cases with determination of MIC values. Scandinavian Journal of Infectious Diseases 28, 311-6.
38. Mehta, R. T., Poddar, S., Kalidas, M., Gomez Flores, R. & Dulski, K. (1997). Role of macrophage activation in the candidacidal activity of liposomal amphotericin B. Journal of Infectious Diseases 175, 214-7.
39. Sievers, T. M., Kubak, B. M. & Wong-Beringer, A. (1996). Safety and efficacy of Intralipid emulsions of amphotericin B. Journal of Antimicrobial Chemotherapy 38, 333-47.
40. Hiddemann, W., Essink, M. E., Fegeler, W., Zuhlsdorf, M., Sauerland, C. & Buchner, T. (1991). Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoeitic cells after intensive cytostatic therapy for acute mycloid leukemia. Cancer 68, 9-14.
41. Thaler, M., Pastakia, B., Shawker, T. H., O'Leary, T. & Pizzo, P. A. (1988). Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Annals of Internal Medicine 108, 88-100.
42. Walsh, T. J., Rubin, M., Hathorn, J., Gress, J., Thaler, M., Skelton, J. et al. (1991). Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. Archives of Internal Medicine 151, 765-70.
43. Wingard, J. R., Vaughan, W. P., Braine, H. G., Merz, W. G. & Saral, R. (1987). Prevention of fungal sepsis in patients with prolonged neutropenia: a randomised, double-blind, placebo-controlled trial of intravenous miconazole. American Journal of Medicine 83, 1103-10.
44. Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E. & Saral, R. (1991). Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New England Journal of Medicine 325, 1274-7.
45. Hitchcock, C. A., Pye, G. W., Troke, P. F., Johnson, E. M. & Warnock, D. W. (1993). Fluconazole resistance in Candida glabrata. Antimicrobial Agents and Chemotherapy 37, 1962-5.
46. Anaissie, E., Bodey, G. P., Kantarjian, H., David, C., Barnett, K., Bow, E. et al. (1991). Fluconazole therapy for chronic disseminated candidiasis in patients with leukaemia and prior amphotericin B therapy. American Journal of Medicine 91, 142-50.
47. Kauffman, C. A., Bradley, S. F., Ross, S. C. & Weber D. R. (1991). Hepatosplenic candidiasis: successful treatment with fluconazole. American Journal of Medicine 91, 137-41.
48. Anaissie, E. J., Darouiche, R. O., Abi-Said, D., Uzun, O., Mera, J., Gentry, L. O. et al. (1996). Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clinical Infectious Diseases 23, 964-72.
49. Anaissie, E. J., Vartivarian, S. E., Abi-Said, D., Uzun, O., Pinczowski, H., Kontoyiannis, D. P. et al. (1996). Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. American Journal of Medicine 101, 170-6.
50. Working Party of the British Society for Antimicrobial Chemotherapy. (1991). Laboratory monitoring of antifungal chemotherapy. Lancet 337, 1577-80.
51. Dupont, B. (1990). Itraconazole therapy in aspergillosis: study in 49 patients. Journal of the American Academy of Dermatology 23, 607-14.
52. van't Wout, J. W., Novakova, I., Verhagen, C. A. H., Fibbe, W. E., de Pauw, B. E. & van der Meer, J. W. M. (1991). The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. Journal of Infection 22, 45-52.
53. Denning, D. W., Lee, J. Y., Hostetler, J. S., Pappas, P., Kauffman, C. A., Dewsnup, D. H. et al. (1994). NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. American Journal of Medicine 97, 135-44.
54. Prentice, A. G., Warnock, D. W., Johnson, S. A. N., Phillips, M. J. & Oliver, D. A. (1994). Multiple dose pharmacokinetics of oral solution of itraconazole in autologous bone marrow transplant patients. Journal of Antimicrobial Chemotherapy 34, 247-52.
55. Bradford, C. R., Prentice, A. G., Warnock, D. W. & Copplestone, J. A. (1991). Comparison of multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. Journal of Antimicrobial Chemotherapy 28, 555-60.
56. Tucker, R. M., Haq, Y., Denning, D. W. & Stevens, D. A. (1990). Adverse events associated with itraconazole in 189 patients on chronic therapy. Journal of Antimicrobial Chemotherapy 26, 561-6.
57. Bohme, A., Ganser, A. & Hoelzer, D. (1995). Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Annals of Hematology 71, 311-2.
58. Novakova, I., Donnelly, P., deWitte, T., de Pauw, B., Boezeman, J., Weltman, G. et al. (1987). Itraconazole and cyclosporin nephrotoxicity. Lancet ii, 920-1.
59. Sud, I. J. & Feingold, D. S. (1983). Effects of ketoconazole on the fungicidal action of amphotericin B in Candida albicans. Antimicrobial Agents and Chemotherapy 23, 185-7.
60. Odds, F. C. (1982). Interactions among amphotericin B, 5-fluorocytosine, ketoconazole and miconazole against pathogenic fungi in vitro. Antimicrobial Agents and Chemotherapy 22, 763-70.
61. Hay, R. J. (1991). Clinical manifestations and management of cryptococcosis in the compromised patient. In Fungal Infections in The Compromised Patient, 2nd edn (Warnock, E. W. & Richardson, M. D., Eds), pp. 85-115. John Wiley, Chichester.
62. Sugar, A. M. (1992). Mucormycosis. Clinical Infectious Diseases 14, Suppl. 1, 126-9.
63. Boelaert, J. R. (1994). Mucormycosis (zygomycosis): is there news for the clinician? Journal of Infection 28, Suppl. 1, 1-6.
64. Skahan, K. J., Wong, B. & Armstrong D. (1991). Clinical manifestations and management of mucormycosis in the compromised patient. In Fungal Infections in The Compromised Patient, 2nd edn (Warnock, D. W. & Richardson, M. D., Eds), pp. 153-90. John Wiley, Chichester.
65. Tedder, M., Spratt, J. A., Anstadt, M. P., Hegde, S. S., Tedder, S. D. & Lowe, J. E. (1994). Pulmonary mucormycosis: results of medical and surgical therapy. Annals of Thoracic Surgery 57, 1044-50.
66. Rabodonirina, M., Piens, M. A., Monier, M. F., Guého, E., Fiére, D. & Mojon, M. (1994). Fusarium infections in immunocompromised patients: case reports and literature review. European Journal of Clinical Microbiology and Infectious Diseases 13, 152-61.
67. Warnock, D. W. & Johnson, E. M. (1991). Clinical manifestations and management of hyalohyphomycoses, phaeohyphomycosis and other uncommon forms of fungal infection in the compromised patient. In Fungal Infections in The Compromised Patient, 2nd edn (Warnock, D. W. & Richardson, M. D., Eds), pp. 248-310. John Wiley, Chichester.
68. Goldberg, S. L., Geha, D. J., Marshall, W. F., Inwards, D. J. & Hoagland, H. C. (1993). Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole. Clinical Infectious Diseases 16, 803-5.
69. Anaissie, E. & Bodey, G. P. (1991). Disseminated trichosporinosis: meeting the challenge. European Journal of Clinical Microbiology and Infectious Diseases 10, 711-3.
70. Ahlmen, J., Edebo, L., Eriksson, C., Carlsson, L. & Torgersen, A. K. (1989). Fluconazole therapy for fungal peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a case report. Peritoneal Dialysis International 9, 79-80.
71. Davies, S. F. & Sarosi, G. A. (1991). Clinical manifestations and management of histoplasmosis in the compromised patient. In Fungal Infections in The Compromised Patient, 2nd edn (Warnock, D. W. & Richardson, M. D., Eds), pp. 191-205. John Wiley, Chichester.
72. Wheat, L. J., Connolly-Stringfield, P., Blair, R., Connelly, K., Garringer, T., Katz, B. P. et al. (1992). Effect of successful treatment with amphotericin B on Histoplasma capsulatum variety capsulatum polysaccharide antigen levels in patients with AIDS and histoplasmosis. American Journal of Medicine 92, 153-60.
73. Stevens, D. A. (1991). Clinical manifestation and management of coccidioidomycosis in the compromised patient. In Fungal Infections in The Compromised Patient, 2nd edn (Warnock, D. W. & Richardson, M. D., Eds), pp. 207-14. John Wiley, Chichester.
74. Nemunaitis, J., Shannon-Dorcy, K., Appelbaum, F. R., Meyers, J., Owens, A., Day, R. et al. (1993). Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 82, 1422-7.
75. Dale, D. C. (1994). Potential role of colony-stimulating factors in the prevention and treatment of infectious diseases. Clinical Infectious Diseases 18, Suppl. 2, 180-8.
76. Bodey, G. P., Anaissie, E., Gutterman, J. & Vadhan-Raj, S. (1993). Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clinical Infectious Diseases 17, 705-7.
77. Bodey, G. P. (1994). The potential role of granulocyte-macrophage colony-stimulating factor in therapy of fungal infections: a commentary. European Journal of Clinical Microbiology and Infectious Diseases 13, 363-6.
78. Kullberg, B. J. & van't Wout, J. W. (1994). Cytokines in the treatment of fungal infections. Biotherapy 7, 95-210.